SUNDAY, MAY 31, 2026
11:10am – 11:30am

POST DDW  

Key Abstracts in Liver

Session Learning Objectives:

• Evaluate the longitudinal impact and durability of THR-β agonists, such as resmetirom, using non-invasive diagnostic metrics including VCTE, Agile 4, and FIB-4 in patients with compensated MASH cirrhosis.
• Analyze the histological and metabolic efficacy of emerging extended half-life therapies, including monthly FGF21 analogs, for achieving steatohepatitis resolution in patients with bridging (F2/F3) fibrosis.
• Assess the effect of advanced liver fibrosis on quality of life to provide tailored lifestyle interventions into holistic MASLD management strategies.
• Apply these recent pharmacological advancements to real-world clinical workflows, bridging the gap between novel therapeutic trial data and day-to-day patient-centered care.

Speaker:
Dr. Nashla Hamdan-Perez MD, MSc. (Medical Science)

Staff Hepatologist and Gastroenterologist, St. Joseph’s Health Centre
Unity Health Toronto
Assistant Professor, Department of Medicine, Division of Gastroenterology, University of Toronto

Dr. Nashla Hamdan-Perez is a Hepatologist and Staff Physician at St. Joseph's Health Centre, and an Assistant Professor in the Department of Medicine, Division of Gastroenterology, at the University of Toronto.

She earned her medical degree summa cum laude from Universidad Panamericana and a Master's in Medical Science from the National Autonomous University of Mexico. After specializing in Internal Medicine and Gastroenterology at Medica Sur Hospital - Mayo Clinic Care Network, Mexico City she completed fellowships in Clinical Advanced Hepatology and Liver Transplant at Toronto General Hospital.

With a primary clinical focus on MASLD and Advanced Chronic Liver Disease, Dr. Hamdan-Perez is dedicated to healthcare quality improvement. Certified in Patient Safety and Quality Improvement by the University of Toronto, she leverages digital health